Last reviewed · How we verify
Chlorothiazide Injection
Chlorothiazide inhibits sodium chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of sodium, chloride, and water.
Chlorothiazide inhibits sodium chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of sodium, chloride, and water. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.
At a glance
| Generic name | Chlorothiazide Injection |
|---|---|
| Also known as | Diuril |
| Sponsor | University of Virginia |
| Drug class | Thiazide diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a thiazide diuretic, chlorothiazide blocks the thiazide-sensitive sodium-chloride cotransporter (NCC) in the kidney's distal convoluted tubule. This reduces fluid volume in the body and lowers blood pressure. The drug also has mild vasodilatory properties that contribute to its antihypertensive effect.
Approved indications
- Hypertension
- Edema associated with congestive heart failure
- Edema associated with renal disease
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Hyponatremia
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorothiazide Injection CI brief — competitive landscape report
- Chlorothiazide Injection updates RSS · CI watch RSS
- University of Virginia portfolio CI